Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891430 | 0.88 | DAO (0.55) | DAOHPGDMAPTTSHRMAPK1 | |
| SCHEMBL8252786 | 0.84 | DAO (0.47) | DAOHPGDMAPTTSHRMAPK1 | |
| SCHEMBL8247664 | 0.84 | ADORA3 (0.51) | DAOHPGDMAPTTSHRMAPK1 | |
| SCHEMBL8247693 | 0.81 | PLK1 (0.47) | HPGDMAPTTSHRMAPK1HTT | |
| SCHEMBL8250029 | 0.79 | POLB (0.48) | DAOHPGDMAPTTSHRMAPK1 | |
| SCHEMBL8241911 | 0.77 | KMT2A (0.44) | DAOHPGDMAPTALDH1A1TDP1 | |
| SCHEMBL18464810 | 0.77 | DAO (0.43) | DAOFEN1CYP1A2MEN1KMT2A | |
| SCHEMBL891366 | 0.77 | LMNA (0.64) | DAOHPGDMAPTTSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL2985946 | 0.76 | LMNA (0.62) | DAOHPGDMAPTTSHRMAPK1 | |
| SCHEMBL8242667 | 0.76 | POLB (0.45) | HPGDMAPTTSHRMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268273-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | claimed |
| EP-1986622-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORP (US) | 2013-10-02 | — | — | EP | claimed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | claimed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | claimed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | claimed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | claimed |
| EP-2268273-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-8618155-B2 | Small-molecule modulators of Trp-p8 activity | DENDREON CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-8614243-B2 | Small-molecule modulators of Trp-p8 activity | DENDREON CORPORATION (US) | 2013-12-24 | — | — | US | disclosed |
| EP-1986622-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORP (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2510925-A2 | Small-Molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-04-05 | — | — | US | disclosed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | TRPC4, TRPC3, TRPC1 | DAO 4148/4885HPGD 1644/4885MAPT 3585/4885 |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | DAO 4148/4885HPGD 1644/4885MAPT 3585/4885 |
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | DAO 4148/4885HPGD 1644/4885MAPT 3585/4885 |
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | DAO 4148/4885HPGD 1644/4885MAPT 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.